Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Krishnan Shanmuganandan"'
Publikováno v:
Journal of Medical and Allied Sciences, Vol 10, Iss 1, Pp 37-40 (2020)
Here, we report a case of dermatomyositis following intradermal allergen testing. 50 year old lady had nasobronchial allergy of 2 years duration in form of nasal stuffiness, for which she underwent intradermal allergen testing. Followed this she deve
Externí odkaz:
https://doaj.org/article/11e908e1064b462f8319bdd4db0d5396
Autor:
M N Arjun, Vivek Vasdev, Kunal Kishore, Arun Hegde, Krishnan Shanmuganandan, Abhishek Kumar, Uday Bhanu Kovilapu, Roopa Shivashankar
Publikováno v:
Indian Journal of Rheumatology, Vol 15, Iss 3, Pp 165-170 (2020)
Background: Intra-articular (IA) platelet-rich plasma (PRP) is a promising treatment option for knee osteoarthritis (OA). It accelerates the process of healing, ligament repair, cartilage regeneration, and bone formation when given in supraphysiologi
Externí odkaz:
https://doaj.org/article/91b6e0cc55714fe88a7e6d50f3e9e494
Autor:
Arun Hegde, Vivek Vasdev, Krishnan Shanmuganandan, Kavita Singh, Sivasami Kartik, Abhishek Kumar
Publikováno v:
Indian Journal of Rheumatology, Vol 13, Iss 1, Pp 20-25 (2018)
Background: Rituximab (RTX), an anti-CD 20 monoclonal antibody is one of the first line biological disease-modifying anti-rheumatoid drug indicated for the treatment of rheumatoid arthritis (RA) in patient's refractory to conventional Synthetic DMARD
Externí odkaz:
https://doaj.org/article/5c3b4bfd25b643c88b1fa1109d54c165
Autor:
M N Arjun, Arun Hegde, Krishnan Shanmuganandan, Darshan S Bhakuni, Kavita Singh, Abhishek Kumar
Publikováno v:
Indian Journal of Rheumatology, Vol 13, Iss 3, Pp 163-167 (2018)
Background: T-cells are pathogenic in rheumatoid arthritis (RA) and have an important role in persistent synovitis, even in established disease. Modulation of T-cell activity by blocking of costimulatory signals has been known to suppress inflammatio
Externí odkaz:
https://doaj.org/article/d05693d4ad3e4684850c24606dfe5b67
Autor:
S.K. Patnaik, Darshan S. Bhakuni, Arun Hegde, Aprajita Bhayana, Abhishek Kumar, Ashwini Kumar, Gautam Mullick, R. P. Singh, Krishnan Shanmuganandan, Vivek Vasdev
Publikováno v:
Med J Armed Forces India
Background Time and cost constraints lead to majority of clinical laboratories deviating away from an ideal practice of checking for antinuclear antibodies (ANAs) by indirect immunofluorescence (IIF) at multiple dilutions. Usage of screening dilution
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::884a2a6c015637fd015f32522f8b060f
https://doi.org/10.1016/j.mjafi.2020.03.008
https://doi.org/10.1016/j.mjafi.2020.03.008
Publikováno v:
International Journal of Biology, Pharmacy and Allied Sciences. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b7ce7d743420d9f1d269c2a977c9aac
https://doi.org/10.31032/ijbpas/2021/10.11.5743
https://doi.org/10.31032/ijbpas/2021/10.11.5743
Autor:
Krishnan Shanmuganandan
Publikováno v:
International Journal of Biology, Pharmacy and Allied Sciences. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e32b13f5ca94d1eadd52212ae33e779
https://doi.org/10.31032/ijbpas/2021/10.11.5742
https://doi.org/10.31032/ijbpas/2021/10.11.5742
Publikováno v:
International Journal of Biology, Pharmacy and Allied Sciences. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04e9a162334a1cf8733a7de8be4f73ed
https://doi.org/10.31032/ijbpas/2021/10.11.5744
https://doi.org/10.31032/ijbpas/2021/10.11.5744
Autor:
MN Arjun, Krishnan Shanmuganandan, Arun Hegde, Kunal Kishore, Vivek Vasdev, Uday Bhanu Kovilapu, Abhishek Kumar, Roopa Shivashankar
Publikováno v:
Indian Journal of Rheumatology, Vol 15, Iss 3, Pp 165-170 (2020)
Background: Intra-articular (IA) platelet-rich plasma (PRP) is a promising treatment option for knee osteoarthritis (OA). It accelerates the process of healing, ligament repair, cartilage regeneration, and bone formation when given in supraphysiologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b941f2899269ca1978912f302bb821ab
http://www.indianjrheumatol.com/article.asp?issn=0973-3698
http://www.indianjrheumatol.com/article.asp?issn=0973-3698
Autor:
Kavita Singh, Abhishek Kumar, Sivasami Kartik, Krishnan Shanmuganandan, Arun Hegde, Vivek Vasdev
Publikováno v:
Indian Journal of Rheumatology, Vol 13, Iss 1, Pp 20-25 (2018)
Background: Rituximab (RTX), an anti-CD 20 monoclonal antibody is one of the first line biological disease-modifying anti-rheumatoid drug indicated for the treatment of rheumatoid arthritis (RA) in patient's refractory to conventional Synthetic DMARD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b6780575a486692c0782d50040e1b4d
http://www.indianjrheumatol.com/article.asp?issn=0973-3698
http://www.indianjrheumatol.com/article.asp?issn=0973-3698